LB Pharmaceuticals advances LB-102 into Phase 3 schizophrenia trial NOVA-2

• LB Pharmaceuticals presented new preclinical findings on LB-102’s mechanism at the 39th ECNP Congress on Oct. 10, 2026.
• Data indicated LB-102 may boost dopamine signaling, supporting a potential path to ease anhedonia and low motivation in mood disorders.
• An encore poster at the same meeting presented previously reported Phase 2 NOVA-1 analyses suggesting cognitive gains were largely a direct drug effect.
• Program updates outlined ongoing late-stage studies: Phase 3 NOVA-2 in schizophrenia, NOVA-3 extension, ILLUMINATE-1 Phase 2 in bipolar depression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610100800PRIMZONEFULLFEED9841833) on October 10, 2026, and is solely responsible for the information contained therein.